NKGen Biotech, Inc.
NKGNDelisted Jul 17, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001845459
NKGen Biotech, Inc. was delisted on Jul 17, 2025; its insiders filed their last Form 4 on Jun 2, 2025; no institution reported holding it in 13F filings for Q2 2025; no superinvestor held it.
13F holders, Q4 2024
Institutional positions in NKGen Biotech, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- +6 vs. Q3 2024
- Shares held
- 8.35M
- +4.60M (+122.5%) vs. Q3 2024
- Total value
- $5.07M
- +$3.84M (+312.2%) vs. Q3 2024
- New holders
- 9
- 4 more added
- Sold out
- 3
- 5 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NKGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $165.4K |
| Q1 2026 | 1 | $192.9K |
| Q4 2025 | 1 | $137.8K |
| Q3 2025 | 1 | $303.2K |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 3 | $160.8K |
| Q4 2024 | 25 | $5.07M |
| Q3 2024 | 19 | $1.23M |
| Q2 2024 | 17 | $4.24M |
| Q1 2024 | 13 | $5.66M |
| Q4 2023 | 9 | $13.7M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding NKGen Biotech, Inc.; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 500,000 | $0 | 0.00% | −681,872−57.7% | Reduced |
| JPMorgan Chase & Co | 45 | $29 | 0.00% | +14+45.2% | Added |
| Bank of America Corp | 102 | $67 | 0.00% | −4−3.8% | Reduced |
| Federation des caisses Desjardins du Quebec | 500 | $328 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 763 | $500 | 0.00% | −13,883−94.8% | Reduced |
| SBI Securities Co., Ltd. | 902 | $591 | 0.00% | +902 | New |
| BlackRock, Inc. | 1,854 | $1.22K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 2,782 | $1.82K | 0.00% | −8,953−76.3% | Reduced |
| State Street Corp | 11,200 | $7.34K | 0.00% | 00.0% | Unchanged |
| SkyOak Wealth, LLC | 13,164 | $8.63K | 0.00% | +13,164 | New |
| Two Sigma Investments, LP | 22,356 | $14.6K | 0.00% | +22,356 | New |
| Two Sigma Securities, LLC | 22,495 | $14.7K | 0.00% | −1,980−8.1% | Reduced |
| Periscope Capital Inc. | 25,000 | $16.4K | 0.01% | +25,000 | New |
| Northern Trust Corp | 29,082 | $19.1K | 0.00% | 00.0% | Unchanged |
| XTX Topco Ltd | 33,625 | $22.0K | 0.00% | +33,625 | New |
| Advisory Research Inc | 43,088 | $28.2K | 0.00% | +43,088 | New |
| Geode Capital Management, LLC | 127,168 | $83.3K | 0.00% | +14,454+12.8% | Added |
| Magnetar Financial LLC | 267,508 | $95.5K | 0.00% | +267,508 | New |
| Sequoia Financial Advisors, LLC | 156,000 | $102.2K | 0.00% | +87,000+126.1% | Added |
| Vanguard Group Inc | 227,804 | $149.2K | 0.00% | 00.0% | Unchanged |
| Kepos Capital LP | 230,022 | $151.0K | 0.13% | +230,022 | New |
| Diametric Capital, LP | 518,134 | $339.5K | 0.23% | 00.0% | Unchanged |
| University of Chicago | 550,000 | $360.4K | 0.34% | 00.0% | Unchanged |
| Meteora Capital, LLC | 2,772,145 | $1.82M | 0.65% | +1,887,400+213.3% | Added |
| Pathstone Holdings, LLC | 2,797,661 | $1.83M | 0.01% | +2,797,661 | New |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −95,438−100.0% | Sold out |
| Towneley Capital Management, Inc | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| HRT Financial LP | 0 | $0 | 0.00% | −10,318−100.0% | Sold out |